Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study

•Pembrolizumab and nab-paclitaxel were evaluated in 70 patients with platinum-treated, metastatic urothelial carcinoma.•The median PFS was 5.9 months, the objective response rate was 38.6%, and the median duration of response was not reached.•Grade 3–4 treatment-related adverse events were observed in 17 patients (24.3%).•This study presented results from one of the first salvage chemoimmunotherapy regimens in advanced urothelial carcinoma....